Rational design of a booster vaccine against COVID-19 based on antigenic distance

Hu, Ye-Fan; Yuen, Terrence Tsz-Tai; Gong, Hua-Rui; Hu, Bingjie; Hu, Jing-Chu; Lin, Xuan-Sheng; Rong, Li; Zhou, Coco Luyao; Chen, Lin-Lei; Wang, Xiaolei; Lei, Chaobi; Yau, Thomas; Hung, Ivan Fan-Ngai; To, Kelvin Kai-Wang; Yuen, Kwok-Yung; Zhang, Bao-Zhong; Chu, Hin; Huang, Jian-Dong

doi:10.1016/j.chom.2023.07.004

Cited by 5 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, a recent study reported that administering a SARS‐CoV‐1‐based booster after two priming doses of the BNT162b2 vaccine results in enhanced breadth and durability of neutralizing response. These findings suggest immune imprinting from prior SARS‐CoV‐1 infection 18 years ago and employing SARS‐CoV‐1 as a booster yields divergent outcomes of antibody response 25 . One limitation in this study is that the two groups were not matched for age and the median age of individuals in SARS‐CoV‐1 survivor group (62 years) is higher than healthy control group (39 years), which might contribute to the compromised antibody responses in the former group.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS‐CoV‐1 survivors after two doses of CoronaVac plus one dose subunit vaccine

Chen,

Li,

Hao

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron harbors more than 30 mutations of the spike protein and exhibits substantial immune evasion. Although previous study indicated that BNT162b2 messenger RNA vaccine induces potent cross‐clade pan‐sarbecovirus neutralizing antibodies in survivors of the infection by SARS‐CoV‐1, the neutralization activity and Fc‐mediated effector functions of these cross‐reactive antibodies elicited in SARS‐CoV‐1 survivors to Omicron subvariants still remain largely unknown. In this study, the neutralization activity and Fc‐mediated effector functions of antibodies boosted by a third dose vaccination were characterized in SARS‐CoV‐1 convalescents and healthy individuals. Potent cross‐clade broadly neutralizing antibodies were observed in SARS‐CoV‐1 survivors who received a three‐dose vaccination regimen consisting of two priming doses of CoronaVac followed by one booster dose of the protein subunit vaccine ZF2001. However, the induced antibodies exhibited both reduced neutralization and impaired Fc effector functions targeting multiple Omicron subvariants. Importantly, the data also support the notion that immune imprints resulted from SARS‐CoV‐1 infection may exacerbate the impairment of neutralization activity and Fc‐mediated effector functions to Omicron subvariants and provided invaluable information to vaccination strategy in future.

show abstract

Section: Discussionmentioning

confidence: 96%

“…These findings suggest immune imprinting from prior SARS-CoV-1 infection 18 years ago and employing SARS-CoV-1 as a booster yields divergent outcomes of antibody response. 25 One limitation in this study is that the two groups were not matched for strains. The similar phenomena were also observed in SARS-CoV-2 infection.…”

Section: Discussionmentioning

confidence: 99%

Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS‐CoV‐1 survivors after two doses of CoronaVac plus one dose subunit vaccine

Chen,

Li,

Hao

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Nanoparticles in Subunit Vaccines: Immunological Foundations, Categories, and Applications

Liang,

Yao,

Liu

et al. 2024

Small

View full text Add to dashboard Cite

Subunit vaccines, significant in next‐generation vaccine development, offer precise targeting of immune responses by focusing on specific antigens. However, this precision often comes at the cost of eliciting strong and durable immunity, posing a great challenge to vaccine design. To address this limitation, recent advancements in nanoparticles (NPs) are utilized to enhance antigen delivery efficiency and boost vaccine efficacy. This review examines how the physicochemical properties of NPs influence various stages of the immune response during vaccine delivery and analyzes how different NP types contribute to immune activation and enhance vaccine performance. It then explores the unique characteristics and immune activation mechanisms of these NPs, along with their recent advancements, and highlights their application in subunit vaccines targeting infectious diseases and cancer. Finally, it discusses the challenges in NP‐based vaccine development and proposes future directions for innovation in this promising field.

show abstract

COVID-19 vaccine updates for people under different conditions

Huang,

Wang,

Liu

et al. 2024

Sci. China Life Sci.

View full text Add to dashboard Cite

Rational design of a booster vaccine against COVID-19 based on antigenic distance

Cited by 5 publications

References 79 publications

Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS‐CoV‐1 survivors after two doses of CoronaVac plus one dose subunit vaccine

Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS‐CoV‐1 survivors after two doses of CoronaVac plus one dose subunit vaccine

Nanoparticles in Subunit Vaccines: Immunological Foundations, Categories, and Applications

COVID-19 vaccine updates for people under different conditions

Contact Info

Product

Resources

About